Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 7/10

vs
industry
vs
history
Cash to Debt No Debt
GERN's Cash to Debt is ranked higher than
95% of the 1250 Companies
in the Global Biotechnology industry.

( Industry Median: 67.35 vs. GERN: No Debt )
GERN' s 10-Year Cash to Debt Range
Min: 0.87   Max: No Debt
Current: No Debt

Equity to Asset 0.95
GERN's Equity to Asset is ranked higher than
96% of the 937 Companies
in the Global Biotechnology industry.

( Industry Median: 0.68 vs. GERN: 0.95 )
GERN' s 10-Year Equity to Asset Range
Min: 0.37   Max: 0.97
Current: 0.95

0.37
0.97
F-Score: 4
Z-Score: 32.10
M-Score: 19.28
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 2/10

vs
industry
vs
history
Operating margin (%) -3048.00
GERN's Operating margin (%) is ranked higher than
54% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -75.73 vs. GERN: -3048.00 )
GERN' s 10-Year Operating margin (%) Range
Min: -41916.67   Max: -149.32
Current: -3048

-41916.67
-149.32
Net-margin (%) -3000.33
GERN's Net-margin (%) is ranked higher than
54% of the 1026 Companies
in the Global Biotechnology industry.

( Industry Median: -78.15 vs. GERN: -3000.33 )
GERN' s 10-Year Net-margin (%) Range
Min: -41504.17   Max: -131.51
Current: -3000.33

-41504.17
-131.51
ROE (%) -32.48
GERN's ROE (%) is ranked higher than
75% of the 1147 Companies
in the Global Biotechnology industry.

( Industry Median: -34.77 vs. GERN: -32.48 )
GERN' s 10-Year ROE (%) Range
Min: -157.29   Max: -17.94
Current: -32.48

-157.29
-17.94
ROA (%) -30.77
GERN's ROA (%) is ranked higher than
72% of the 1253 Companies
in the Global Biotechnology industry.

( Industry Median: -27.49 vs. GERN: -30.77 )
GERN' s 10-Year ROA (%) Range
Min: -85.77   Max: -14.86
Current: -30.77

-85.77
-14.86
ROC (Joel Greenblatt) (%) -44823.53
GERN's ROC (Joel Greenblatt) (%) is ranked lower than
51% of the 1227 Companies
in the Global Biotechnology industry.

( Industry Median: -437.61 vs. GERN: -44823.53 )
GERN' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -7309.19   Max: -89.68
Current: -44823.53

-7309.19
-89.68
Revenue Growth (3Y)(%) -37.00
GERN's Revenue Growth (3Y)(%) is ranked higher than
63% of the 728 Companies
in the Global Biotechnology industry.

( Industry Median: -2.20 vs. GERN: -37.00 )
GERN' s 10-Year Revenue Growth (3Y)(%) Range
Min: 0   Max: 58.7
Current: -37

0
58.7
EBITDA Growth (3Y)(%) -35.50
GERN's EBITDA Growth (3Y)(%) is ranked higher than
58% of the 714 Companies
in the Global Biotechnology industry.

( Industry Median: -5.80 vs. GERN: -35.50 )
GERN' s 10-Year EBITDA Growth (3Y)(%) Range
Min: -35.5   Max: 13.5
Current: -35.5

-35.5
13.5
EPS Growth (3Y)(%) -35.90
GERN's EPS Growth (3Y)(%) is ranked higher than
60% of the 729 Companies
in the Global Biotechnology industry.

( Industry Median: -7.40 vs. GERN: -35.90 )
GERN' s 10-Year EPS Growth (3Y)(%) Range
Min: -35.9   Max: 32.5
Current: -35.9

-35.9
32.5
» GERN's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q4 2013

GERN Guru Trades in Q4 2013

Paul Tudor Jones 18,396 sh (New)
Jean-Marie Eveillard 6,511 sh (unchged)
Steven Cohen Sold Out
Jim Simons Sold Out
Chuck Royce Sold Out
Jean-Marie Eveillard 2,085,827 sh (-17.1%)
» More
Q1 2014

GERN Guru Trades in Q1 2014

John Burbank 25,000 sh (New)
Jean-Marie Eveillard 3,054,252 sh (+46.43%)
Jean-Marie Eveillard 2,013 sh (unchged)
Paul Tudor Jones Sold Out
» More
Q2 2014

GERN Guru Trades in Q2 2014

Jean-Marie Eveillard 3,548,124 sh (+16.17%)
John Burbank 25,000 sh (unchged)
» More
Q3 2014

GERN Guru Trades in Q3 2014

John Burbank 25,000 sh (unchged)
Jean-Marie Eveillard 2,198,124 sh (-38.05%)
» More
» Details

Insider Trades

Latest Guru Trades with GERN

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Jean-Marie Eveillard 2014-09-30 Reduce -38.05%0.01%$2.12 - $3.014 $ 3.0624%2198124
Jean-Marie Eveillard 2014-03-31 Add 46.43%0.01%$1.6 - $5.4 $ 3.06-24%3054252
John Burbank 2014-03-31 New Buy$1.6 - $5.4 $ 3.06-24%25000
Jean-Marie Eveillard 2013-03-31 Add 36.91%$1.01 - $1.64 $ 3.06122%2410934
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/B 3.50
GERN's P/B is ranked higher than
80% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 6.25 vs. GERN: 3.50 )
GERN' s 10-Year P/B Range
Min: 1.07   Max: 12.04
Current: 3.5

1.07
12.04
EV-to-EBIT -9.70
GERN's EV-to-EBIT is ranked higher than
56% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9999.00 vs. GERN: -9.70 )
GERN' s 10-Year EV-to-EBIT Range
Min: -16.7   Max: -0.3
Current: -9.7

-16.7
-0.3
Current Ratio 18.13
GERN's Current Ratio is ranked higher than
94% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.73 vs. GERN: 18.13 )
GERN' s 10-Year Current Ratio Range
Min: 3.19   Max: 33.57
Current: 18.13

3.19
33.57
Quick Ratio 18.13
GERN's Quick Ratio is ranked higher than
94% of the 1242 Companies
in the Global Biotechnology industry.

( Industry Median: 4.57 vs. GERN: 18.13 )
GERN' s 10-Year Quick Ratio Range
Min: 3.19   Max: 33.57
Current: 18.13

3.19
33.57

Valuation & Return

vs
industry
vs
history
Price/Net Cash 4.00
GERN's Price/Net Cash is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 53.79 vs. GERN: 4.00 )
GERN' s 10-Year Price/Net Cash Range
Min: 1.45   Max: 223.42
Current: 4

1.45
223.42
Price/Net Current Asset Value 4.00
GERN's Price/Net Current Asset Value is ranked higher than
91% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 31.40 vs. GERN: 4.00 )
GERN' s 10-Year Price/Net Current Asset Value Range
Min: 1.45   Max: 141.11
Current: 4

1.45
141.11
Price/Tangible Book 3.50
GERN's Price/Tangible Book is ranked higher than
85% of the 1337 Companies
in the Global Biotechnology industry.

( Industry Median: 9.45 vs. GERN: 3.50 )
GERN' s 10-Year Price/Tangible Book Range
Min: 1.25   Max: 18.35
Current: 3.5

1.25
18.35
Earnings Yield (Greenblatt) -10.30
GERN's Earnings Yield (Greenblatt) is ranked higher than
68% of the 1221 Companies
in the Global Biotechnology industry.

( Industry Median: -6.20 vs. GERN: -10.30 )
GERN' s 10-Year Earnings Yield (Greenblatt) Range
Min: -10.3   Max: 0
Current: -10.3

-10.3
0

Business Description

Industry: Biotechnology » Biotechnology
Compare:NVO, AMGN, GILD, BIIB, CELG » details
Traded in other countries:GON.Germany,
Geron Corp was incorporated in the State of Delaware on November 28, 1990. It is a clinical stage biopharmaceutical company developing a telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company operates in the segment of the discovery and development of therapeutic products for oncology. It owns worldwide commercial rights with U.S. patent coverage extending through 2025 for imetelstat. Its patent rights relating to telomerase cover the cloned genes that encode the RNA component and the catalytic protein component of human telomerase, cells that are immortalized by expression of recombinant hTERT, and cancer diagnostics based on detecting the expression of telomerase in cancer cells. The Company is subject to various and often changing federal, state, local and international laws, rules, regulations, guidelines and recommendations relating to safe working conditions and manufacturing practices.
» More Articles for GERN

Headlines

Articles On GuruFocus.com
Weekly CEO Buys Highlight: IBTX, INSM, GERN, INO, EQU Apr 07 2013 
WEEKLY CFO SELLS HIGHLIGHT: HTM, OVTI, VSEA, KSWS,GERN, ATRC Jun 20 2011 
Geron Corp. Reports Operating Results (10-Q) Oct 29 2010 
Geron: Buyer Beware Oct 13 2010 
Geron Corp. (GERN) President and CEO Thomas Okarma sells 18,874 Shares Jun 03 2010 
Geron Corp. (GERN) EVP and CFO David Greenwood sells 14,746 Shares Jun 03 2010 
Geron Corporation Reports 2009 Second Quarter Financial Results and Events Jul 30 2009 
Geron Corp (GERN): Stock of the Day Mar 10 2009 
Banking 60% on the Day the World Changed: FDA Approves Geron to Test Embryonic Stem Cells on Humans Jan 24 2009 
The Next Boom Emerges Nov 23 2008 

More From Other Websites
Geron reports 3Q loss Dec 17 2014
Geron reports 3Q loss Dec 17 2014
GERON CORP Files SEC form 8-K, Other Events, Financial Statements and Exhibits Dec 16 2014
Geron Announces Early HSR Clearance for Global Strategic Collaboration with Janssen Dec 16 2014
Geron Announces Early HSR Clearance for Global Strategic Collaboration with Janssen Dec 16 2014
Why Geron Corporation (GERN) Stock Might be a Great Pick Dec 10 2014
Geron to Host Analyst and Investor Meeting on December 8 Dec 05 2014
Geron to Host Analyst and Investor Meeting on December 8 Dec 05 2014
Geron (GERN) Stock: Moving Average Crossover Alert Dec 05 2014
Geron Announces Publication of Preclinical Data on Imetelstat Activity in Acute Myelogenous Leukemia Dec 04 2014
Geron Announces Publication of Preclinical Data on Imetelstat Activity in Acute Myelogenous Leukemia Dec 04 2014
Geron to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
Geron to Present at the 26th Annual Piper Jaffray Healthcare Conference Nov 26 2014
Geron (GERN) Showing Signs Of A Dead Cat Bounce Today Nov 26 2014
Strong On High Relative Volume: Geron (GERN) Nov 21 2014
The Zacks Analyst Blog Highlights: Geron, Gilead, Regeneron, Celldex Therapeutics and AbbVie Nov 20 2014
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU Nov 19 2014
Can the Rally in Geron (GERN) Shares Continue? Nov 19 2014
GERON CORP Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits Nov 18 2014
Incyte Building Blockbuster Drug One Disease At A Time Nov 17 2014

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK